5/17/2005 Toronto, Ontario, Canada press release Newswire Canada (www.newsire.ca) Viventia Biotech Inc. today announced that it disclosed updated clinical data for its anti-cancer therapeutic, Proxinium(TM) (VB4-845), in two poster presentations on Saturday, May 14th given at the 2005 American Society of Clinical Oncology's (ASCO) annual meeting in Orlando, Florida being held from May 13-17, 2005. Dr. Nick Glover, President and CEO of Viventia Biotech, commented: "In these poster presentations, we provided an update on previously disclosed clinical data demonstrating that Proxinium(TM) has a good safety profile and beyond this, that the drug can produce very encouraging efficacy results including a demonstrable survival benefit in patients with refractory head & neck cancer." The first poster presented by the Company (Abstract No. 5569) entitled "A Phase I study of VB4-845 in patients with advanced, recurrent head & neck cancer on a weekly dosing scheme," disclosed updated results from an exploratory Phase I efficacy trial using direct intratumoral injection of Proxinium(TM) as a monotherapy. A total of 20 patients were enrolled in the study and 18 were considered evaluable at the end of the trial. VB4-845 administered on a weekly basis for 4 weeks was safe and well tolerated. The maximum tolerated dose (MTD) on this schedule was determined to be 930 (micro) g/day. Preliminary results from this study were previously described in a press release dated March 29th, 2005. Although this study was primarily designed to evaluate safety and tolerability, clinical observations indicated that VB4-845 demonstrated promising anti-tumor responses against Ep-CAM-positive SCCHN [...]

5/17/2005 Toronto, Ontario, Canada press release Newswire Canada (www.newswire.ca) Patients being treated with high dose radiation for head and neck cancer in the morning have a lower risk of developing debilitating side effects than patients who receive treatment in the late afternoon, suggests new research by oncologists at the Toronto Sunnybrook Regional Cancer Centre, the comprehensive cancer program at Sunnybrook and Women's College Health Sciences Centre. Funded by the Canadian Cancer Society and the Canadian Institutes of Health Research, the clinical trial found a condition called mucositis was much less common in patients who received high-dose radiation treatment early in the day compared to the end of the afternoon. Mucositis is damage to the lining of the mouth and throat that is sometimes so severe that treatment must be stopped. The research presented yesterday at the American Society of Clinical Oncology Annual Meeting, is the first to show a link between circadian rhythms and the development of mucositis due to radiotherapy. The study is based on research lead by medical oncologist Dr. Georg Bjarnason from Sunnybrook & Women's who is internationally known for his research on circadian rhythms and cancer. "In a previous study on healthy volunteers, we discovered a variation in the cell division cycle of cells in the mouth over a 24-hour period. In the morning, the cells in the lining of the mouth are in a phase of cell division that is relatively resistant to radiotherapy, whereas in the afternoon these cells are in a phase that [...]

5/17/2005 Orlando, FL press release EurekAlert (www.eurekalert.com) Study shows RADPLAT treatment shows promise against tough-to-treat cancer Researchers studying an innovative treatment for advanced head-and-neck cancer, combining chemotherapy and radiation, report that about half of patients were still alive four years after treatment. Radiation Therapy Oncology Group physicians announced results from their phase II study at the American Society of Clinical Oncology annual meeting on May 14. The treatment, called RADPLAT, combines radiation and a platinum-based chemotherapy drug called cisplatin. What makes the treatment unique is that instead of providing chemotherapy intravenously, oncologists inject cisplatin through tiny catheters directly into the arteries that feed the tumor, sending the drug exactly where it is needed. "Our results were extremely encouraging," says study presenter Parvesh Kumar, M.D., professor and chair of radiation oncology at the Keck School of Medicine of the University of Southern California and USC/Norris Comprehensive Cancer Center. "The benefits seen in patients with advanced, inoperable disease were comparable to benefits seen with the same therapy in patients with earlier-stage disease. "Based on these favorable results, we should certainly consider a bigger phase III clinical trial for this technique in a wider, broader group of patients." Physicians at 11 university medical centers recruited 67 patients for the study, and performed the treatment in 61 patients. Patients had stage IV-T4 disease: Tumors were large and inoperable. Squamous cell carcinoma is difficult to treat successfully in this advanced stage. Tumor sites ranged from the mouth to the larynx. The oncologists inserted catheters into [...]

5/17/2005 Orlando, FL press release Business Wire (www.businesswire.com) OSI Pharmaceuticals provided a second informational update summarizing highlights from presentations on Tarceva(TM) (erlotinib) made at the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO) being held from May 14-17 in Orlando, Fla. The presentations included data from two separate single-arm Phase II studies of monotherapy Tarceva in chemotherapy-naive or front-line non-small cell lung cancer patients. Both studies indicated encouraging indications of anti-tumor activity for monotherapy Tarceva in this setting. Another presentation based on data from the BR.21 study concluded that patients on Tarceva had slower deterioration of their disease-related symptoms of cough, dyspnea and pain and that these differences were clinically and statistically significant. Encouraging indications of anti-tumor activity were also reported in several Phase II studies outside of NSCLC including combination therapy data for Tarceva with Avastin in renal cell carcinoma, Tarceva with chemotherapy in head and neck cancer and monotherapy use of Tarceva in colorectal and hepatocellular cancer. Highlights included: Phase II Study of Combination Cisplatin, Docetaxel and Erlotinib in Patients with Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) - E.S. Kim (Abstract #5546) Encouraging preliminary data was presented from an ongoing Phase II trial combining Tarceva with cisplatinum and docetaxel in HNSCC. Results were reported for the 22 patients evaluable for response. Complete response was reported in 3 patients (13 percent), partial response was reported in 14 patients (64 percent) and 4 patients (18 percent) were reported having stable disease. Responses were documented using [...]

5/16/2005 Chicago, IL Reuters staff Reuters Alert Net (www.alertnet.org) Statin drugs commonly used to lower cholesterol and fight heart disease appear to cut the risk of pancreatic and throat cancer by more than half, a study said on Monday. It was the latest in a number of reports to attribute anti-cancer properties to statins, and comes after Saturday's release in Florida of a study involving 40,000 women that found the drugs lowered the risk of breast cancer by 51 percent. Earlier reports also have ascribed a protective effect to statins for prostate and colon cancers, though why they may limit tumor growth in both humans and test animals has not been clear. The latest finding "suggests that these compounds may have health benefits that extend well beyond the heart and may affect the entire body," said John Johanson, a physician at the University of Illinois. He made the comment in a report released at an annual meeting of gastrointestinal experts, where Monday's study from U.S. Veterans Administration doctors was presented. The study involved nearly half a million U.S. veterans, mostly men, under treatment from 1998 to 2004. One part of the study found that statins were associated with a 56 percent reduced incidence of esophageal cancer, after age, gender, smoking and alcohol use were taken into account. A second part of the study found a 59 percent reduced risk of pancreatic cancer after taking into account the same factors. "The results should be interpreted with caution," the study said, because [...]

5/15/2005 Atlanta, GA Medical News Staff Medical News Today (www.medicalnewstoday.com) Binding gold nanoparticles to a specific antibody for cancer cells could make cancer detection much easier, suggests research at the Georgia Institute of Technology and the University of California at San Francisco (UCSF). The report is published online as an ASAP article in the journal Nano Letters. “Gold nanoparticles are very good at scattering and absorbing light,” said Mostafa El-Sayed, director of the Laser Dyanamics Laboratory and chemistry professor at Georgia Tech. “We wanted to see if we could harness that scattering property in a living cell to make cancer detection easier. So far, the results are extremely promising.” Many cancer cells have a protein, known as Epidermal Growth Factor Receptor (EFGR), all over their surface, while healthy cells typically do not express the protein as strongly. By conjugating, or binding, the gold nanoparticles to an antibody for EFGR, suitably named anti-EFGR, researchers were able to get the nanoparticles to attach themselves to the cancer cells. “If you add this conjugated nanoparticle solution to healthy cells and cancerous cells and you look at the image, you can tell with a simple microscope that the whole cancer cell is shining,” said El-Sayed. “The healthy cell doesn't bind to the nanoparticles specifically, so you don't see where the cells are. With this technique, if you see a well defined cell glowing, that's cancer.” In the study, researchers found that the gold nanoparticles have 600 percent greater affinity for cancer cells than for [...]

5/15/2005 Prague, Czech Republic R Tachezy et al. Oral Dis, May 1, 2005; 11(3): 181-5 Objective: An association between high-risk human papillomavirus (HR HPV) infection and a risk of development of a subgroup of head and neck cancers has been proposed recently. The main risk factors of oral and oropharyngal cancer observed in our population are smoking and alcohol consumption. The incidence of oral/oropharyngeal tumours in the Czech Republic is relatively high and there are no data available about the prevalence of HPV DNA presence in these tumours. Materials and methods: Eighty patients with a primary oropharyngeal cancer were enrolled. The presence of HPV DNA has been evaluated by polymerase chain reaction in 68 cases from which the tumour tissue and demographical and clinical data were available. The typing of HPV was performed by nucleotide DNA sequencing. Results: The HPV DNA was detected in 51.5% of samples tested. Among the HPV DNA positive tumours, 80% contained HPV16. In the analysed group there were 54 men and 14 women. The prevalence of HPV DNA was lower in oral (25%) than in oropharyngeal (57%) tumours, and higher in never smokers (100%) and never drinkers (68.8%). HPV DNA presence was not related to gender, age, number of lifetime sexual partners or practice of oral-genital sex, size of tumour or presence of regional metastases. Conclusions: The difference in the prevalence of HPV DNA positive tumours between cases of oral cavity and oropharyngeal carcinoma exposed and not exposed to tobacco or alcohol support the theory [...]

5/15/2005 Rome, Italy Enzo Maria Ruggeri et al. Head Neck, May 2, 2005 Background: Neoadjuvant chemotherapy has been reported to be extremely active in head and neck cancer but has failed to give a statistically significant improvement in survival. Methods: From 1981 to 1994, 33 operable patients with locally advanced oral cavity cancer received cisplatin-based chemotherapy before surgery. Postoperative radiotherapy was performed in high-risk patients. Results: The overall clinical and pathologic complete response rates to neoadjuvant chemotherapy were 48% and 30%, respectively. At a median follow-up of 7.0 years (range, 0.3-15.3+ years), the 5-year and 10-year overall survival rates were 54.5% and 39.5%, and the disease-specific median survival was 6.6 years for all patients (8.3 and 2.3 years for stages III and IV, respectively). The univariate analysis showed a positive relationship between survival and male sex (p = .05), pathologic (p = .02), and clinical (p = .03) complete response. The Cox proportional hazard regression model confirmed the independent prognostic value of the clinical response with a 4.67 (95% CI, 1.70-12.86) hazard ratio. A second primary tumor occurred in six patients (18%), with a median of occurrence of 9 years (range, 7-11 years). Conclusions: This study confirms the prolonged survival expectancy largely exceeding 5 years for selected patients with stage IV and for most with stage III locally advanced oral cavity cancer achieving a clinical and/or pathologic complete response to chemotherapy. Authors: Enzo Maria Ruggeri, Paolo Carlini, Camillo Francesco Pollera, Salvatore De Marco, Paolo Ruscito, Paola Pinnaro, Mario Nardi, Diana [...]

5/15/2005 Japan Y Ichimiya et al. Oral Oncol, May 1, 2005; 41(5): 520-5 The medical records of 133 patients with Stage I tongue cancer treated by definitive radiotherapy between 1966 and 2001 were reviewed. Overall survival rate (OS), progression free survival rate (PFS), and survival rate after recurrence were calculated according to the Kaplan-Meier method. We investigated prognostic factors for local control and risk factors of late neck LN metastasis. The 5-year OS was 81.8% and the 5-year PFS was 67.2%. The 5-year OS after local recurrence was 100% by salvage operation, and that after neck LN metastasis was 40.7% despite radical neck dissection. Tumor thickness over 5mm and treatment without interstitial irradiation were prognostic factors for local control. Tumor diameter over 15mm and tumor thickness over 5mm were risk factors of late neck LN metastasis. We should consider prophylactic treatment for neck LN for high risk patients with Stage I tongue cancer in order to improve treatment results further. Authors: Y Ichimiya, N Fuwa, M Kamata, T Kodaira, K Furutani, H Tachibana, N Tomita, and S Hidano Authors Affiliation: Department of Radiation Oncology, Aichi Cancer Center, Aichi 464-8681, Japan

5/15/2005 Bradenton, FL Bradenton Herald (www.bradenton,com) Despite the cigar-smokers-don't-inhale argument, there's no safe level of second-hand smoke, according to Patrick Reynolds, president of Los Angeles-based Foundation for a Smoke Free America and grandson of R.J. Reynolds, the tobacco company founder. Second-hand smoke can cause lung cancer or heart disease, Reynolds said. Cigar smokers may also be exposed to a slew of other cancers including mouth cancer, throat cancer and cancer of the gums. Cigars don't carry the same health warnings as cigarettes and chewing tobacco, but can have more nicotine and tar, and can produce 30 times more carbon monoxide, Reynolds said. "Nicotine in cigars is just as addictive, whether you get it from cigarettes or cigars," Reynolds said. Smoke Free America is a nonprofit group that encourages tobacco-free youth and tobacco prevention. Its Web site is www.anti-smoking.org.